A sophisticated big protein complex is called a proteasome. It is in charge of intracellular protein breakdown. Energy for metabolism is needed. A cellular complex called proteasome inhibitors degrades ubiquitinated proteins by attaching the lysine residue's side chain's amino group. this has become a potent therapy option for multiple myeloma (MM). The first-ever proteasome inhibitor is called bortezomib (PI). Carfilzomib is a PI of the second generation. These PIs have been used in a number of regimens along with other substances such as alkylators, immunomodulatory medicines, and monoclonal antibodies. This study provides an overview of the proteasome, its structure, proteasome inhibitors, biological effects, the outcomes of clinical studies looking at combinations of therapeutic medicines based on PIs, and potential future developments in the Myeloma treatment